-
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
JCI InsightGreenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team. -
Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count.
Endocr RevSo M, Speake C, Steck AK, Lundgren M, Colman PG, Palmer JP, Herold KC, Greenbaum CJ -
Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.
Nat GenetRobertson CC, Inshaw JRJ, Onengut-Gumuscu S, Chen WM, Santa Cruz DF, Yang H, Cutler AJ, Crouch DJM, Farber E, Bridges SL Jr, Edberg JC, Kimberly RP, Buckner JH, Deloukas P, Divers J, Dabelea D, Lawrence JM, Marcovina S, Shah AS, Greenbaum CJ, Atkinson MA, Gregersen PK, Oksenberg JR, Pociot F, Rewers MJ, Steck AK, Dunger DB, Type 1 Diabetes Genetics Consortium., Wicker LS, Concannon P, Todd JA, Rich SS -
Pancreatic islet reserve in type 1 diabetes.
Ann N Y Acad SciFlatt AJS, Greenbaum CJ, Shaw JAM, Rickels MR -
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care.
DiabetesGreenbaum CJ -
Uncovering Pathways to Personalized Therapies in Type 1 Diabetes.
DiabetesLinsley PS, Greenbaum CJ, Nepom GT -
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sci Transl MedSims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC, Type 1 Diabetes TrialNet Study Group. -
Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR.
PLoS OneCortez FJ, Gebhart D, Robinson PV, Seftel D, Pourmandi N, Owyoung J, Bertozzi CR, Wilson DM, Maahs DM, Buckingham BA, Mills JR, Roforth MM, Pittock SJ, McKeon A, Page K, Wolf WA, Sanda S, Speake C, Greenbaum CJ, Tsai CT -
Acute Hyperinsulinemia Alters Bone Turnover in Women and Men With Type 1 Diabetes.
JBMR PlusSherk VD, Vigers T, Pyle L, Snell-Bergeon JK, Nadeau KJ, Rickels MR, Miller KM, Greenbaum CJ, Shah VN -
C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.
Diabetes CareBogun MM, Bundy BN, Goland RS, Greenbaum CJ -
Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes.
DiabetologiaRodrigues KB, Dufort MJ, Llibre A, Speake C, Rahman MJ, Bondet V, Quiel J, Linsley PS, Greenbaum CJ, Duffy D, Tarbell KV -
Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. Diabetes Care 2020;43:913-917.
Diabetes CareSo M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C -
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.
F1000ResLord S, Greenbaum CJ -
Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic β cells.
JCI InsightNeiman D, Gillis D, Piyanzin S, Cohen D, Fridlich O, Moss J, Zick A, Oron T, Sundberg F, Forsander G, Skog O, Korsgren O, Levy-Khademi F, Arbel D, Hashavia S, Shapiro AMJ, Speake C, Greenbaum CJ, Hosford J, Posgai AL, Atkinson MA, Glaser B, Schatz DA, Shemer R, Dor Y -
Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01.
DiabetesArribas-Layton D, Guyer P, Delong T, Dang M, Chow IT, Speake C, Greenbaum CJ, Kwok WW, Baker RL, Haskins K, James EA
